<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2016-07-11 16:59:30Food and Drug Administration Pharmaceutical industry Clinical research Savient pharmaceuticals Pegloticase PEGylation Prescription Drug User Fee Act Validation Clinical trial |
Add to Reading List |
Microsoft Word - Savient Receives Complete Response from FDAdoc | Microsoft Word - FDA Grants Priority Review to Pegloticase BLA FilingdocDocID: 1sopU - View Document |
| Conjugates prepared with aggregate-free proteins - European Patent Office - EPB1 Conjugates prepared with aggregate-free proteins - European Patent Office - EPB1DocID: 1rrGr - View Document |
| Peg-urate oxidase conjugates and use thereof - European Patent Office - EPB1 Peg-urate oxidase conjugates and use thereof - European Patent Office - EPB1DocID: 1rrm1 - View Document |
| Microsoft Word - Savient Press Release ACRdocDocID: 1rrcY - View Document |
| Microsoft Word - Savient Phase 3 Dosing press releasedocDocID: 1ri7E - View Document |